Receives three 483 observations
Shilpa Medicare announced that the US FDA has completed inspection of Company's API facilities Unit-I and Unit-II located at Raichur, Karnataka, India which was inspected between 16 January and 19 January 2018. The inspection has now been closed by the US FDA with three 483 observations. The Company is in the process of submission of corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
